Home Alzheimer’s Disease Early Results from the Phase Ia/b Dose Escalation Trial of CG-806 in...

Early Results from the Phase Ia/b Dose Escalation Trial of CG-806 in CLL/SLL and NHL

Early results from a phase Ia/b dose escalation trial evaluating the safety and tolerability of CG-806 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL) or non-Hodgkin’s lymphomas (NHL) were presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020, held from April 27-28, 2020.1

“CG-806 is an orally bioavailable non-covalent kinase inhibitor that potently inhibits key clusters of related kinases involved in oncogenic signaling,” Rafael Bejar, MD, PhD, chief medical officer for Aptose, said during a poster presentation of the data at AACR.2 “These include the tight cluster of kinases that include BTKITK, and related kinases.”

The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments